Skip to main content

LIGHTPATH TECHNOLOGIES INC

For the period ended Dec 31, 2025. Filed Feb 11, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2025 · Filed Feb 11, 2026

LPTH$7.99-0.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Unaudited Condensed Consolidated Statement of Changes in Stockholders’ Equity

Condensed Consolidated Statements of Changes in Stockholders' Equity

Temporary Equity · Accumulated
Series G Convertible · Class A · Additional · Other · Total
Preferred Stock · Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders’
SharesAmountSharesAmountCapitalIncomeDeficitEquity
Balances at June 30, 202524,956$34,232,51042,949,307$429,493$244,953,346$978,686$(230,716,757)$15,644,768
Issuance of common stock for:
Exercise of stock options, RSUs & RSAs, net——8,58386(86)———
Issuance of common stock under private equity placement——1,600,00016,0007,878,045——7,894,045
Issuance of common stock for acquisition of Visimid——112,3231,123348,877——350,000
Stock-based compensation on stock options, RSUs & RSAs————349,624——349,624
Foreign currency translation adjustment—————92,383—92,383
Net loss——————(2,893,002)(2,893,002)
Balances at September 30, 202524,956$34,232,51044,670,213$446,702$253,529,806$1,071,069$(233,609,759)$21,437,818
Issuance of common stock for:
Exercise of stock options, RSUs & RSAs, net——120,2341,203(1,203)———
Exercise of warrants——739,7307,397(7,397)———
Issuance of common stock under public equity placement——8,912,50089,12565,251,709——65,340,834
Stock-based compensation on stock options, RSUs & RSAs————348,986——348,986
Foreign currency translation adjustment—————212,859—212,859
Net loss——————(9,405,409)(9,405,409)
Balances at December 31, 202524,956$34,232,51054,442,677$544,427$319,121,901$1,283,928$(243,015,168)$77,935,088
Balances at June 30, 2024—$—39,254,643$392,546$245,140,758$509,936$(215,843,575)$30,199,665
Issuance of common stock for:0
Employee Stock Purchase Plan——8,2328210,290——10,372
Exercise of Stock Options, RSUs & RSAs, net——70,309703(703)———
Issuance of common stock for acquisition of Visimid——279,5532,796318,562——321,358
Stock-based compensation on stock options, RSUs & RSAs————264,475——264,475
Foreign currency translation adjustment—————271,594—271,594
Net loss——————(1,622,745)(1,622,745)
Balances at September 30, 2024—$—39,612,737$396,127$245,733,382$781,530$(217,466,320)$29,444,719
Issuance of common stock for:
Exercise of Stock Options, RSUs & RSAs, net——229,0972,291(2,291)———
Shares issued as compensation——49,00049089,180——89,670
Stock-based compensation on stock options, RSUs & RSAs————231,581——231,581
Foreign currency translation adjustment—————(451,035)—(451,035)
Net loss——————(2,611,997)(2,611,997)
Balances at December 31, 2024—$—39,890,834$398,908$246,051,852$330,495$(220,078,317)$26,702,938
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.